Alnylam Pharmaceuticals
ALNY
#543
Rank
C$60.91 B
Marketcap
C$461.11
Share price
-2.52%
Change (1 day)
14.12%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): C$0.17 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are C$3.21 Billion. In 2024 the company made an earning of -C$0.33 Billion, an increase over its 2023 earnings that were of -C$0.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) C$0.17 B-154.33%
2024 -C$0.33 Billion-24.59%
2023 -C$0.43 Billion-67.84%
2022 -C$1.33 Billion36.93%
2021 -C$0.97 Billion-8.04%
2020 -C$1.06 Billion-15.66%
2019 -C$1.25 Billion12.23%
2018 -C$1.12 Billion62.91%
2017 -C$0.69 Billion17.78%
2016 -C$0.58 Billion43.44%
2015 -C$0.41 Billion60.69%
2014 -C$0.26 Billion98.2%
2013 -C$0.13 Billion
2011 -C$74.78 Million27.48%
2010 -C$58.66 Million-10.92%
2009 -C$65.85 Million95.77%
2008 -C$33.64 Million
2006 -C$53.88 Million-9.13%
2005 -C$59.3 Million34.74%
2004 -C$44.01 Million36.79%
2003 -C$32.18 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
C$22.39 B 12,499.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
C$12.41 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
C$7.01 B 3,848.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-C$0.35 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-C$64.7 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-C$0.22 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
C$2.41 B 1,259.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
C$0.19 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA